Ramasastry Saira 4
4 · Mirum Pharmaceuticals, Inc. · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
Mirum (MIRM) Director Saira Ramasastry Exercises Options, Sells Shares
What Happened
- Director Saira Ramasastry exercised stock options and sold shares on April 15, 2026. She exercised 2,000 optioned shares at $23.51 ($47,020 cost) and immediately sold 2,000 shares in the open market at $96.90 for $193,800 in proceeds. The filing also reports a separate derivative conversion of 2,000 shares recorded as disposed at $0.00 (the filing does not explain that entry).
- This sequence (exercise followed by an immediate sale) is effectively an option exercise with a prompt sale of the underlying shares (a common way to realize gains).
Key Details
- Transaction dates: April 15, 2026; Form 4 filed April 16, 2026 (covers 4/15/26).
- Exercise: 2,000 shares at $23.51 = $47,020 (coded M, acquired).
- Sale: 2,000 shares at $96.90 = $193,800 (coded S, disposed).
- Additional derivative entry: 2,000 shares at $0.00 (coded M, disposed); no explanation in the reported excerpt.
- Footnotes: Transaction occurred under a Rule 10b5-1 trading plan adopted Sept 18, 2025 (F1). The stock option exercised was fully vested (F2).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Timeliness: Filing was submitted the day after the transaction (appearance of timely reporting).
Context
- For retail investors: exercises followed by immediate sales are routine ways insiders convert option gains to cash and do not necessarily signal a change in company outlook. The presence of a 10b5-1 plan indicates the sale was pre-planned under an established trading arrangement.
Insider Transaction Report
Form 4
Ramasastry Saira
Director
Transactions
- Exercise/Conversion
Common Stock
2026-04-15$23.51/sh+2,000$47,020→ 2,000 total - Sale
Common Stock
[F1]2026-04-15$96.90/sh−2,000$193,800→ 0 total - Exercise/Conversion
Stock Option (right to buy)
[F2]2026-04-15−2,000→ 2,000 totalExercise: $23.51Exp: 2032-06-01→ Common Stock (2,000 underlying)
Footnotes (2)
- [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.
- [F2]The stock option is fully vested.
Signature
/s/ Judit Ryvkin, Attorney-in-Fact|2026-04-16